A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

This study is testing a new targeted drug called 9MW2821 compared to standard chemotherapy in women with cervical cancer that has come back or spread after prior treatment. The drug is designed to specifically attack cancer cells while minimizing harm to healthy tissue. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have cervical cancer that has returned or spread and cannot be cured with surgery or radiation - Your cancer was confirmed by biopsy and is a squamous cell, HPV-related adenocarcinoma, or mixed type - You have received one or two previous chemotherapy treatments (including a platinum-based drug) and your cancer has progressed - You are in good physical health and able to carry out daily activities - Your organs are functioning well enough to receive additional chemotherapy **You may NOT be eligible if...** - You have a rare type of cervical cancer (HPV-independent adenocarcinoma or neuroendocrine) - You have received treatment within the last 3–4 weeks, or certain targeted drugs previously - You have serious heart or brain blood vessel problems in the last 6 months - You have cancer that has spread to the brain - You have moderate-to-severe nerve damage in your hands or feet - You have significant fluid buildup in the lungs, belly, or around the heart Talk to your doctor to see if this trial is right for you.